Skip to content

Insight

Custom aptamers: 5 factors to consider before you begin

From drug screening to critical assay reagents and as targeted therapeutics, aptamers are increasingly being employed across the discovery and development pipeline. Despite the large catalogues of antibodies, aptamers and…

From aptamer to Optimer

Why we do this. What the benefit is for you. Aptamers are increasingly being used across the life sciences in research, diagnostics and therapeutics. We have years of experience in…

Speeding the time-to-clinic with Optimer®

New research shows how Optimer can speed projects by up to 75% compared to standard antibodies. Speeding project timelines can be vital to the development of any life science product. Whether…

Oligo therapeutics vs ADCs. How do they stack up?

  Biologics, such as antibody therapeutics have revolutionised our approach to the treatment of disease. Therapeutic antibodies have become the predominant class of drugs in the development pipeline and the…

Expanding proteomic capabilities with Optimers

The genomic revolution brought simple, sensitive and rapid DNA sequencing, creating a step-change in our biological understanding. Next-generation proteomics is now promising to do the same for protein sequencing…